NOTICE

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY TO ANY U.S. PERSON (AS DEFINED IN REGULATION S ("REGULATION S") OF THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")) OR ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE US VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA OR IN ANY OTHER JURISDICTION IN WHICH IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS NOTICE.

4 December 2025

Praemia Healthcare
(the "Company**")**

ANNOUNCES THE INDICATIVE RESULTS OF THE TENDER OFFER IN RESPECT OF ITS €500,000,000 5.500 PER CENT. SUSTAINABILITY NOTES DUE 19 SEPTEMBER 2028 (OF WHICH €500,000,000 ARE CURRENTLY OUTSTANDING) (ISIN: FR001400KL23) ADMITTED TO TRADING ON THE REGULATED MARKET OF EURONEXT PARIS (THE "EXISTING NOTES**")**

This notice must be read in conjunction with the tender offer memorandum dated 26 November 2025 (the "*Tender Offer Memorandum****") which has been prepared by the Company in relation to the Tender Offer. Capitalised terms used in this notice and not otherwise defined herein shall have the meanings ascribed to them in the Tender Offer Memorandum.***

On 26 November 2025, the Company announced the launch of a Tender Offer to Qualifying Holders (as defined in the Tender Offer Memorandum) of their Existing Notes. Under the terms of the Tender Offer, Qualifying Holders (subject to offer restrictions) were invited to tender their Existing Notes for purchase by the Company for cash up to a Target Consideration Amount (*i.e.* €150,000,000).

The Tender Offer expired at 4:00 p.m., Paris time, on 3 December 2025.

Indicative Results of the Tender Offer

- Target Consideration Amount (i.e. the estimated total cash spend on tender, including accrued): approximately €162,000,000
- Aggregate nominal amount of Existing Notes validly tendered and accepted for purchase: approximately €150,000,000
- Pro-ration Factor: 40.945 %

The above is non-binding and subject to confirmation at the time of the announcement of the final results of the Tender Offer, which will take place as soon as reasonably practicable after the Pricing Time (as defined below).

Interpolated Mid-Swap Rate, Tender Yield and Tender Price

The Interpolated Mid-Swap Rate, the Tender Yield and the Tender Price for the Existing Notes shall be determined at or around 12:30 p.m. (Paris time) today (the "**Pricing Time**") in the manner described in the Tender Offer Memorandum.

Final Results of the Tender Offer

Subject to the satisfaction or waiver of the Transaction Condition, and provided the Company has not elected to withdraw, amend, extend or terminate the Tender Offer prior to the Pricing Time in accordance with the Tender Offer Memorandum, and as soon as reasonably practicable after the Pricing Time, the Company will announce:

(i) the Final Tender Consideration Amount;

(ii) the Final Acceptance Amount;

(iii) the Pro-ration Factor (if any);

(iv) the Interpolated Mid-Swap Rate, the Tender Yield and the Tender Price; and

(v) the aggregate nominal amount of Existing Notes that will remain outstanding after the Settlement Date,

by way of announcements to be submitted to the Clearing Systems and published on a Notifying News Service, on the website of Euronext Paris (www.euronext.com) and of the Company (www.praemia-healthcare.fr).

Settlement Date of the Tender Offer, subject to the satisfaction or waiver of the Transaction Condition

The Company announced on 26 November 2025 its intention, subject to market conditions, to issue euro-denominated sustainability notes (the "**New Notes**"). The settlement date of the Tender Offer is expected to take place on the latest of (i) 8 December 2025 and (ii) 1 Business Day after the settlement of the New Notes (the "**Settlement Date**"). All sales pursuant to the Tender Offer will settle through the normal procedures of Euroclear France, Euroclear and Clearstream. On the Settlement Date, the Company shall pay or procure the payment on its behalf, to each Qualifying Holder which has validly submitted an Offer to Participate by the Expiration Deadline, of an amount in cash corresponding to the Tender Consideration (*i.e.* an amount in cash equal to the product of (i) the aggregate nominal amount of the Existing Notes validly tendered and accepted for purchase by the Company and (ii) the Tender Price plus Accrued Interest Amount for such Existing Notes as are accepted for purchase by the Company in its sole discretion).

Contact Information

The Dealer Managers of the Tender Offer are:

DEALER MANAGERS

BNP PARIBAS

16 boulevard des Italiens
75009 Paris
France
Tel: +33 1 55 77 78 94
Attn: Liability Management Group
Email: liability.management@bnpparibas.com

BofA Securities Europe SA

51 rue La Boétie
75008 Paris
France
Tel: +33 1 87 70 10 57
Attn: Liability Management Group
Email: dg.lm-emea@bofa.com

Crédit Agricole Corporate and Investment Bank

12 place des États-Unis
CS70052
92547 Montrouge Cedex
France
Tel: +44 207 214 5903
Attn: Liability Management
Email: liability.management@ca-cib.com

The Information Agent for the Tender Offer is:

Kroll Issuer Services Limited
The Shard
32 London Bridge Street
London SE1 9SG
United Kingdom
Tel: +44 (0)20 7704 0880
Email: praemia@is.kroll.com

The Tender Agent for the Tender Offer is:

Société Générale
32, rue du Champ de Tir
CS 30812
44308 Nantes Cedex
France
Tel: +33 (0) 2 51 85 68 29
Email: nantes.gis-op-titres@sgss.socgen.com

Copies of the Tender Offer Memorandum are available upon request addressed to the Information Agent. Prior to making a decision as to whether to participate in the Tender Offer, Qualifying Holders should carefully consider all of the information in the Tender Offer Memorandum.

OFFER RESTRICTIONS

The distribution of this notice in certain jurisdictions may be restricted by law. Persons into whose possession this notice or the Tender Offer Memorandum comes are required by each of the Company, the Dealer Managers, the Information Agent and the Tender Agent to inform themselves about, and to observe, any such restrictions. Please see the Tender Offer Memorandum for a full description of such restrictions.